- Details
- Alicia Morgans and Oliver Sartor discuss the New England Journal of Medicine editorial on the fifteen-year follow-up of the ProtecT trial. The ProtecT trial was a UK-based study where 1600 men were randomized to either active monitoring, prostatectomy, or radiotherapy. The trial followed up on these men for 15 years and found that there were no significant differences in mortality between the grou...
|
- Details
- In this conversation, Alicia Morgans speaks with Professor David Penson about the ProtecT trial and its implications for clinical practice. The study found no difference in outcomes between surgery, radiation, and conservative management in prostate cancer patients after 10 years of follow-up. However, a recent 15-year follow-up has revealed some new findings. The cohort of patients enrolled in th...
|
- Details
- Zachary Klaassen is joined by Neil Mariados, the lead author on both the SpaceOAR™ and Barrigel® trials to discuss rectal spacing, which is used in radiation therapy to reduce rectal toxicity in prostate cancer patients. Rectal spacing involves inserting a gel between the rectum and the prostate to create a space that reduces the dose to the rectum during radiation. They compare the two FDA-approv...
|
- Details
- Matt Cooperberg interviews Tyler Seibert, a radiation oncologist and assistant professor at UC San Diego. They focus on the use of MRI for localized prostate cancer, which has drastically changed the diagnostic pathway for prostate cancer in the last decade. However, the variability in the way the MRI is conducted is a problem. Each imaging center sets up its own protocol, and this lack of coordin...
|
- Details
- The single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen [PSA] > 0.2 ng/mL)-free rate in patients with high-risk localized prostate cancer (HR-LPC) after radical prostatectomy following adjuvant apalutamide and androgen-deprivation therapy. In this substudy, relugolix, an oral gonadotropin-releasing hormone antagonist,...
|
- Details
- In this UroToday Journal Club, Zachary Klaassen highlights the Urologic Oncology publication entitled Out-of-pocket costs for commercially insured patients with localized prostate cancer. Financial burdens may contribute to long-term effects on patient's health-related quality of life. However, costs are rarely included in shared decision-making conversations, and most studies available have focus...
|
- Details
- Zachary Klaassen discusses The Journal of Urology publication entitled "Association Between Treatment for Localized Prostate Cancer and Mental Health." This study compares patient-reported mental health outcomes for men undergoing treatment for localized prostate cancer over 5 years using the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study. Biographies: Zachary Klaassen,...
|
- Details
- In this UroToday Journal Club, Zach Klaassen highlights a European Urology Oncology publication entitled Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-Based Biopsy in Men on Active Surveillance for Prostate Cancer -- Data from the Multi-International Multicenter Prospective PRIAS Study . In general, the use of MRI prior to initial biopsy is now relatively widely manda...
|
- Details
- In this UroToday Journal Club, Zach Klaassen highlights a European Urology publication entitled High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium . Radiotherapy is a standard-of-care treatment approach for patients with localized prostate cancer, and t...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review The Lancet Oncology publication High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05) looking at its 10-year results. Radiotherapy is a standard treatment option in patients with localized prostate cancer. With conventional dosing of radiotherapy, the addition of androgen...
|
